⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4728794 | 0.82 | KDM4E (0.52) | — | |
| SCHEMBL15617823 | 0.82 | NPC1 (0.43) | — | |
| SCHEMBL4190714 | 0.80 | KDM4E (0.50) | — | |
| SCHEMBL9895103 | 0.76 | — | — | |
| SCHEMBL2537108 | 0.76 | — | — | |
| SCHEMBL641980 | 0.76 | — | — | |
| SCHEMBL15546309 | 0.76 | — | — | |
| SCHEMBL3230992 | 0.76 | KDM4E (0.46) | — | |
| SCHEMBL3464071 | 0.76 | — | — | |
| SCHEMBL152133 | 0.76 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250049772-A1 | PIPERIDINYL-3-(ARYLOXY)PROPANAMIDES AND PROPANOATES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2025-02-13 | — | — | US | disclosed |
| EP-4452944-A1 | CYCLOPROPYL COMPOUNDS | Icagen, LLC (US) | 2024-10-30 | — | — | EP | disclosed |
| US-20240336571-A1 | NOVEL CYCLOPROPYL COMPOUNDS | ANGELINI PHARMA S.P.A. (IT) | 2024-10-10 | — | — | US | disclosed |
| WO-2024134541-A1 | HETEROCYCLIC COMPOUNDS AS ENT INHIBITORS AND COMPOUNDS FOR USE IN THE TREATMENT OF CANCERS | iTeos Belgium SA (BE) | 2024-06-27 | — | — | WO | disclosed |
| US-12005054-B2 | Piperidinyl-3-(aryloxy)propanamides and propanoates | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2024-06-11 | — | — | US | disclosed |
| CN-112236423-B | Piperidinyl-3- (aryloxy) propanamides and propionic acid esters | 武田药品工业株式会社 | 2024-02-06 | — | — | CN | disclosed |
| WO-2023121992-A1 | CYCLOPROPYL COMPOUNDS | ICAGEN, LLC (US) | 2023-06-29 | — | — | WO | disclosed |
| US-20230021834-A1 | PIPERIDINYL-3-(ARYLOXY)PROPANAMIDES AND PROPANOATES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-01-26 | — | — | US | disclosed |
| CN-114703078-A | Chryseobacterium indolerum and application thereof | 沈阳恩柽研究院有限公司 | 2022-07-05 | — | — | CN | disclosed |
| US-11045457-B2 | Piperidinyl-3-(aryloxy)propanamides and propanoates | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-06-29 | — | — | US | disclosed |
| US-8969347-B2 | Compounds and methods for treating inflammatory and fibrotic disorders | INTERMUNE, INC. | 2015-03-03 | — | — | US | disclosed |
| US-20140235637-A1 | COMPOUNDS AND METHODS FOR TREATING INFLAMMATORY AND FIBROTIC DISORDERS | INTERMUNE, INC. (US) | 2014-08-21 | — | — | US | disclosed |
| US-20130102597-A1 | COMPOUNDS AND METHODS FOR TREATING INFLAMMATORY AND FIBROTIC DISORDERS | INTERMUNE, INC. (US) | 2013-04-25 | — | — | US | disclosed |
| US-8304413-B2 | Compounds and methods for treating inflammatory and fibrotic disorders | INTERMUNE, INC. (US) | 2012-11-06 | — | — | US | disclosed |
| EP-2296653-A1 | COMPOUNDS AND METHODS FOR TREATING INFLAMMATORY AND FIBROTIC DISORDERS | Intermune, Inc. (US) | 2011-03-23 | — | — | EP | disclosed |
| US-20090318455-A1 | COMPOUNDS AND METHODS FOR TREATING INFLAMMATORY AND FIBROTIC DISORDERS | INTERMUNE, INC. (US) | 2009-12-24 | — | — | US | disclosed |
| WO-2009149188-A1 | COMPOUNDS AND METHODS FOR TREATING INFLAMMATORY AND FIBROTIC DISORDERS | INTERMUNE, INC. (US) | 2009-12-10 | — | — | WO | disclosed |
| EP-1204663-A1 | NOVEL SPIRO COMPOUNDS | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2002-05-15 | — | — | EP | disclosed |
| WO-2001014376-A1 | NOVEL SPIRO COMPOUNDS | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2001-03-01 | — | — | WO | disclosed |
| EP-0204535-A1 | N-fluoropyridinium salt and process for preparing same | SAGAMI CHEMICAL RESEARCH CENTER (JP) | 1986-12-10 | — | — | EP | disclosed |